CARTESIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.29 USD | -6.83% |
|
-21.35% | +31.95% |
| Jun. 04 | Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target | MT |
| May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 107 | 521.2 | - | - |
| Enterprise Value (EV) 1 | 107 | 253.8 | 144.1 | 260.1 |
| P/E ratio | -0.42 x | -3.01 x | -5.64 x | -6.67 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 4.11 x | 32.2 x | 42.4 x | 38 x |
| EV / Revenue | 4.11 x | 15.7 x | 11.7 x | 19 x |
| EV / EBITDA | - | -4.09 x | -1.5 x | -2.03 x |
| EV / FCF | - | -4.09 x | -2.37 x | -3.25 x |
| FCF Yield | - | -24.4% | -42.3% | -30.8% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,173 | 17,796 | - | - |
| Reference price 2 | 20.68 | 27.29 | 27.29 | 27.29 |
| Announcement Date | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 26 | 16.17 | 12.29 | 13.7 |
| EBITDA 1 | - | - | -62 | -96 | -128 |
| EBIT 1 | - | -86.42 | -51.33 | -63.69 | -81.01 |
| Operating Margin | - | -332.32% | -317.37% | -518.22% | -591.09% |
| Earnings before Tax (EBT) 1 | -6.455 | -238.7 | -87.85 | -59.98 | -89.84 |
| Net income 1 | -6.455 | -219.7 | -93.93 | -66.2 | -86.67 |
| Net margin | - | -844.91% | -580.79% | -538.59% | -632.44% |
| EPS 2 | - | -49.80 | -9.078 | -4.835 | -4.093 |
| Free Cash Flow 1 | - | - | -62 | -60.94 | -80.16 |
| FCF margin | - | - | -383.36% | -495.81% | -584.91% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.84 | 5.393 | 2.536 | 2.536 | - | - |
| EBITDA 1 | - | -17 | -15 | -16 | - | - |
| EBIT 1 | -13.35 | -9.939 | -14.01 | -14.22 | -14.75 | -15.12 |
| Operating Margin | -228.56% | -184.3% | -552.34% | -560.99% | - | - |
| Earnings before Tax (EBT) 1 | -56.82 | -3.707 | -10.89 | -11.34 | -13.07 | -13.96 |
| Net income 1 | -56.82 | -8.616 | -13.16 | -13.5 | -14.29 | -14.73 |
| Net margin | -973.01% | -159.77% | -518.84% | -532.54% | - | - |
| EPS 2 | -10.50 | -0.6383 | -1.135 | -1.123 | -1.700 | -1.700 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 267 | 377 | 261 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -62 | -60.9 | -80.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 2.2 | 0.53 | 0.52 |
| Capex / Sales | - | - | 13.63% | 4.32% | 3.77% |
| Announcement Date | 1/23/24 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
27.29
USD
Average target price
43.83
USD
Spread / Average Target
+60.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.95% | 521M | |
| +18.15% | 124B | |
| +18.02% | 111B | |
| -12.75% | 23.17B | |
| +5.07% | 22.94B | |
| -39.94% | 17.42B | |
| -9.86% | 17.42B | |
| -14.97% | 16.9B | |
| +2.80% | 13.71B | |
| +27.39% | 11.82B |
- Stock Market
- Equities
- RNAC Stock
- Financials Cartesian Therapeutics, Inc.
